Abbott Q2 Earnings Drop on Exact Sciences Acquisition Costs; Legal Overhang Persists
ABT sits 31% above its 52-week low of $81.97.
Summary
Abbott's Q2 2026 earnings dropped sharply due to costs tied to its Exact Sciences acquisition, while revenue grew 13%. Legal risks remain elevated after an appeals court upheld a $495 million NEC verdict.
Key Events · Earnings and Guidance · ABT
-
Earnings Decline on Acquisition Costs
Q2 net earnings fell 48% to $928M ($0.53 diluted EPS) from $1,779M ($1.01) a year ago, as higher interest expense ($351M vs $121M) and intangible amortization ($658M vs $420M) from the Exact Sciences deal weighed on profits.
-
Revenue Growth Driven by Exact Sciences
Total net sales rose 13% to $12.6B, with Diagnostic Products surging 42% to $3.1B, including $919M from the new Cancer Diagnostics unit. Medical Devices grew 9% to $5.9B.
-
Balance Sheet Transformation
Total assets jumped to $109.2B from $86.7B at year-end, with long-term debt soaring to $29.6B from $9.9B after issuing $20B in notes to fund the acquisition. Goodwill and intangibles increased to $52.5B.
-
Legal Setback in NEC Litigation
The Missouri Court of Appeals affirmed a $495M plaintiff verdict in the Gill NEC case. Abbott is seeking review by the Missouri Supreme Court. No reserves have been recorded for NEC cases due to uncertainty.
Analysis · ABT · Life Sciences
Abbott's Q2 net earnings fell 48% to $928 million, driven by higher interest expense and amortization from the $20.6 billion Exact Sciences acquisition. While revenue grew 13% to $12.6 billion, the bottom line was pressured by integration costs and a jump in debt. The balance sheet reflects the deal's full impact: long-term debt surged to $29.6 billion, and goodwill/intangibles nearly doubled. On the legal front, a Missouri appeals court affirmed a $495 million verdict in an NEC infant formula case, and Abbott is seeking further review. The company also settled a shareholder derivative lawsuit. These legal outcomes add uncertainty, though Abbott maintains no reserves for the NEC cases. The quarter underscores the near-term earnings drag from the transformative acquisition, even as the top line benefits from the new cancer diagnostics segment.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABT was trading at $107.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $186.8B. The 52-week trading range was $81.97 to $137.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.